Breaking News Instant updates and real-time market news.

ZLAB

Zai Lab

$22.84

0.21 (0.93%)

, TSRO

Tesaro

$74.36

-0.26 (-0.35%)

07:45
01/09/19
01/09
07:45
01/09/19
07:45

Zai Lab completes enrollment in niraparib Phase 3 trial

Zai Lab (ZLAB) announced completion of patient enrollment of its pivotal trial of niraparib, or Zejula in development for second-line maintenance therapy in patients with recurrent, platinum-sensitive ovarian cancer. The Phase 3 trial is evaluating niraparib as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer. Recurrent ovarian cancer patients who have responded to a platinum-containing regimen were enrolled in the study and randomized 2:1 to receive either niraparib or placebo once daily. Patients were stratified by gBRCA status. The primary endpoint is progression-free survival. The study enrolled its first patient in September 2017. Zai Lab in-licensed rights to Zejula from Tesaro (TSRO) for China, Hong Kong and Macau as an important, new treatment option to more than 50,000 Chinese patients who suffer from ovarian cancer every year. Zejula is positioned as a PARP inhibitor due to its efficacy, once-daily dosing and pharmacokinetic properties including its ability to cross the blood brain barrier. The NDA was accepted by the NMPA in December 2018. Zai Lab obtained approval for marketing Zejula in Hong Kong in October and launched the product in December 2018. Niraparib is also being evaluated in China in pivotal studies as first-line maintenance therapy in platinum-sensitive ovarian cancer and in small-cell lung cancer.

ZLAB

Zai Lab

$22.84

0.21 (0.93%)

TSRO

Tesaro

$74.36

-0.26 (-0.35%)

  • 09

    Jan

  • 17

    Jan

ZLAB Zai Lab
$22.84

0.21 (0.93%)

02/14/18
JPMS
02/14/18
UPGRADE
Target $35
JPMS
Overweight
Zai Lab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Zai Lab to Overweight and raised his price target for the shares to $35 from $32. The analyst continues to view the company as an attractive healthcare emerging markets story in China, and now believes shares represent an attractive long-term entry point. The analyst adds that the FPA144 deal is an "underappreciated oncology tuck-in, with a meaningful target market opportunity."
06/21/18
LEER
06/21/18
INITIATION
Target $43
LEER
Outperform
Zai Lab assumed with an Outperform at Leerink
Leerink analyst Jonathan Chang assumed coverage of Zai Lab with an Outperform rating and $43 price target as he believes it is well-positioned to execute.
11/21/18
JEFF
11/21/18
INITIATION
Target $34
JEFF
Buy
Zai Lab initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Zai Lab with a Buy rating and $34 price target. The analyst likes the company's structure of forming partnerships around assets that are already clinically de-risked. The partnerships reduce risk and allow Zai Lab to accelerate a drug's path to market in China, Raycroft tells investors in a research note.
TSRO Tesaro
$74.36

-0.26 (-0.35%)

12/05/18
CANT
12/05/18
DOWNGRADE
Target $75
CANT
Neutral
Tesaro downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young downgraded Tesaro (TSRO) to Neutral to reflect the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $68.
12/10/18
LEHM
12/10/18
DOWNGRADE
Target $75
LEHM
Equal Weight
Tesaro downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Tesaro (TSRO) to Equal Weight citing the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $48.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.

TODAY'S FREE FLY STORIES

RARX

RA Pharmaceuticals

$19.59

1 (5.38%)

07:26
02/22/19
02/22
07:26
02/22/19
07:26
Initiation
RA Pharmaceuticals initiated  »

RA Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$38.98

-0.03 (-0.08%)

07:26
02/22/19
02/22
07:26
02/22/19
07:26
Periodicals
TSMC getting traction for AI, 5G 'boom' with its EUV process, DigiTimes says »

The upcoming Mobile World…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$41.10

-0.05 (-0.12%)

07:26
02/22/19
02/22
07:26
02/22/19
07:26
Downgrade
Teradyne rating change  »

Teradyne downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

  • 28

    May

INTU

Intuit

$234.85

-1.06 (-0.45%)

07:25
02/22/19
02/22
07:25
02/22/19
07:25
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

AAOI

Applied Optoelectronics

07:25
02/22/19
02/22
07:25
02/22/19
07:25
Downgrade
Applied Optoelectronics rating change  »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

ANIK

Anika Therapeutics

$40.45

0.45 (1.13%)

07:24
02/22/19
02/22
07:24
02/22/19
07:24
Downgrade
Anika Therapeutics rating change  »

Anika Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOPE

Grand Canyon

$118.12

20.99 (21.61%)

07:24
02/22/19
02/22
07:24
02/22/19
07:24
Recommendations
Grand Canyon analyst commentary  »

Grand Canyon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIN

Dine Brands

$99.45

10.93 (12.35%)

07:23
02/22/19
02/22
07:23
02/22/19
07:23
Recommendations
Dine Brands analyst commentary  »

Dine Brands price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFRX

InflaRx

$31.65

-0.83 (-2.56%)

07:23
02/22/19
02/22
07:23
02/22/19
07:23
Initiation
InflaRx initiated  »

InflaRx initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNVGY

Lenovo

$0.00

(0.00%)

07:22
02/22/19
02/22
07:22
02/22/19
07:22
Upgrade
Lenovo rating change  »

Lenovo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GWPH

GW Pharmaceuticals

$143.86

-2.16 (-1.48%)

07:21
02/22/19
02/22
07:21
02/22/19
07:21
Initiation
GW Pharmaceuticals initiated  »

GW Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ROKU

Roku

$51.47

-2.16 (-4.03%)

07:21
02/22/19
02/22
07:21
02/22/19
07:21
Downgrade
Roku rating change  »

Roku downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$12.33

-0.32 (-2.53%)

07:20
02/22/19
02/22
07:20
02/22/19
07:20
Hot Stocks
Navient issues statement regarding Canyon nomination of four directors for board »

Navient issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XNCR

Xencor

$32.22

-1.54 (-4.56%)

07:20
02/22/19
02/22
07:20
02/22/19
07:20
Downgrade
Xencor rating change  »

Xencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

GBT

Global Blood Therapeutics

$50.04

-0.45 (-0.89%)

07:19
02/22/19
02/22
07:19
02/22/19
07:19
Initiation
Global Blood Therapeutics initiated  »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FIT

Fitbit

$6.62

-0.03 (-0.45%)

07:18
02/22/19
02/22
07:18
02/22/19
07:18
Downgrade
Fitbit rating change  »

Fitbit downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

STMP

Stamps.com

, FDX

FedEx

$182.28

0.52 (0.29%)

07:18
02/22/19
02/22
07:18
02/22/19
07:18
Recommendations
Stamps.com, FedEx, UPS, Amazon.com analyst commentary  »

Stamps.com should return…

STMP

Stamps.com

FDX

FedEx

$182.28

0.52 (0.29%)

UPS

UPS

$111.76

0.68 (0.61%)

AMZN

Amazon.com

$1,619.84

-2.26 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ARGX

Argenx

$122.20

-2.84 (-2.27%)

07:18
02/22/19
02/22
07:18
02/22/19
07:18
Initiation
Argenx initiated  »

Argenx initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$418.66

-3.9 (-0.92%)

07:17
02/22/19
02/22
07:17
02/22/19
07:17
Initiation
Regeneron initiated  »

Regeneron assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

  • 11

    Mar

  • 28

    Apr

  • 13

    May

BIIB

Biogen

$320.99

-14.02 (-4.18%)

07:15
02/22/19
02/22
07:15
02/22/19
07:15
Initiation
Biogen initiated  »

Biogen assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    May

MGLN

Magellan Health

$70.81

-1.6 (-2.21%)

07:15
02/22/19
02/22
07:15
02/22/19
07:15
Hot Stocks
Starboard to nominate full slate for election to Magellan Health board »

Starboard Value, one of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MO

Altria Group

$50.38

-0.14 (-0.28%)

07:14
02/22/19
02/22
07:14
02/22/19
07:14
Periodicals
Despite flavored vape ban, Juul sees $3.4B in revenue in 2019, Bloomberg says »

Despite the fact that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$127.56

-2.17 (-1.67%)

07:12
02/22/19
02/22
07:12
02/22/19
07:12
Initiation
Alexion initiated  »

Alexion initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

MCRB

Seres Therapeutics

$5.83

-0.07 (-1.19%)

07:11
02/22/19
02/22
07:11
02/22/19
07:11
Initiation
Seres Therapeutics initiated  »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 18

    May

TREE

LendingTree

$310.22

-4.78 (-1.52%)

07:11
02/22/19
02/22
07:11
02/22/19
07:11
Recommendations
LendingTree analyst commentary  »

LendingTree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 14

    Mar

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.